Affiliations 

  • 1 Department of Medical Oncology, University of Antwerp, AZ KLINA, Brasschaat, Belgium
  • 2 Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
  • 3 Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • 4 Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
  • 5 Champalimaud Clinical and Research Centre, Champalimaud Foundation, Lisbon, Portugal
  • 6 Department of Epidemiology, University of Malaya, Kuala Lumpur, Malaysia
  • 7 Just4Cancer, Las Vegas, United States
  • 8 Mammographie-Screening Neckar-Alb, Tübingen, Germany
  • 9 Division of Breast Surgical Oncology, Department of Surgery, Showa University, Tokyo, Japan
  • 10 Department of Radiation and Clinical Oncology, University of Nigeria Teaching Hospital, Enugu, Nigeria
  • 11 Virginia Biomedical Laboratories, Wirtz, VA, United States
Oncologist, 2024 Jul 05;29(7):e899-e909.
PMID: 38780115 DOI: 10.1093/oncolo/oyae080

Abstract

Breast cancer care is a costly global health issue where effective management depends on early detection and treatment. A breast cancer diagnosis can result in financial catastrophe especially in low- and middle-income countries (LMIC). Large inequities in breast cancer care are observed and represent a global challenge to caregivers and patients. Strategies to improve early diagnosis include awareness and clinical breast examination in LMIC, and screening in high-income countries (HIC). The use of clinical guidelines for the management of breast cancer is needed. Adapted guidelines from HIC can address disparities in populations with limited resources. Locally developed strategies still provide effective guidance in improving survival. Integrated practice units (IPU) with timely multidisciplinary breast care conferences and patient navigators are required to achieve high-value, personalized breast cancer management in HIC as well as LMIC. Breast cancer patient care should include a quality of life evaluation using ideally patient-reported outcomes (PROM) and experience measurements (PREM). Evaluation of breast cancer outcomes must include the financial cost of delivered care. The resulting value perspective should guide resource allocation and program priorities. The value of care must be improved by translating the findings of social and economic research into practice and resolving systemic inequity in clinical breast cancer research. Cancer survivorship programs must be put in place everywhere. The treatment of patients with metastatic breast cancer must require more attention in the future, especially in LMIC.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.